feedback welcome

Citalopram-agomelatine

From Psychiatrynet

(Difference between revisions)
Jump to:navigation, search
[draft revision][draft revision]
Line 5: Line 5:
* '''Before day 0:''' gradually reduce dosage of citalopram/escitalopram to a maximum of 40 mg/day, resp. 20 mg/day.  
* '''Before day 0:''' gradually reduce dosage of citalopram/escitalopram to a maximum of 40 mg/day, resp. 20 mg/day.  
* '''Day 1:''' reduce dosage of citalopram/escitalopram to 20 mg/day, resp. 10 mg/day.
* '''Day 1:''' reduce dosage of citalopram/escitalopram to 20 mg/day, resp. 10 mg/day.
-
* '''Day 8:''' reduce dosage of citalopram/escitalopram to 10 mg/day, resp. 5 mg/day.
+
* '''Day 8:''' stop administration of citalopram/escitalopram.
-
* '''Day 15:''' stop administration of citalopram/escitalopram.
+
 
| start =  
| start =  
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.
-
* '''Day 15:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day. }}
+
* '''Day 8:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day. }}

Revision as of 08:57, 5 June 2009

Citalopram
Type Antidepressant
Group SSRI
links
ATC-code N06AB04
Medscape Citalopram
PubChem 2771
PubMed Citalopram
Kompas (Dutch) citalopram
Wikipedia citalopram
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from citalopram to agomelatine.

Nietinrijdenbord.png Stop citalopram
Eenrichtingbord.png Start agomelatine


The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Navigation
About